Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Sep 29, 2022 (4 years ago)

Atenolol Tablets

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogrel 75mg Tablets

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Atenolol Tablets, USP, 25 mg, 1000-count bottle, Rx only, Manufactured by: ALPHAPHARM PTY LTD, Marketed by: GSMS, Incorporated, Camarillo, CA 93012, USA, NDC 60429-027-10

Affected NDC 60429-0027-10

Compare with the code on your package — it is the most precise check available.

Drug: Atenolol Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Atenolol
NDC 60429-0027
25 mg/1 Tablet
Oral
Golden State Medical Supply, Inc. Rx
Recalling firm
Golden State Medical Supply Inc.
NDC code
60429-027-10
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Sep 29, 2022 · FDA notice with lot numbers
FDA recall number
D-0019-2023 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Atenolol recalls

See all
Class II · Moderate risk

ATENOLOL Tablets

Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.

Terminated Particulate / foreign matter Legacy Pharmaceutical Packaging LLC NDC 68645-493-54 D-0606-2017
Class II · Moderate risk

ATENOLOL Tablets

Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.

Terminated Particulate / foreign matter Zydus Pharmaceuticals USA Inc NDC 68382-023-01 D-0605-2017
Class II · Moderate risk

ZyGenerics ATENOLOL Tablets

Superpotent Drug: A complaint was reported by a pharmacist who stated several tablets were noticeably thicker in appearance.

Terminated Wrong potency / content Zydus Pharmaceuticals USA Inc NDC 68382-022-01 D-0007-2015
Class II · Moderate risk

ATENOLOL Tablet

Labeling:Label Mixup; ATENOLOL, Tablet, 12.5 mg (1/2 of 25 mg) may be potentially mislabeled as VITAMIN B COMPLEX WITH C/FOLIC ACID, Tablet, NDC 60258016001, Pedigree: AD73652_19, EXP: 5/30/2014; PIROXICAM, Capsule, 10 mg, NDC 00093075601, Pedigree: AD21836_1, EXP: 3/31/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-679-2014

Other recalls by Golden State Medical Supply Inc.

All 2022 recalls
Class II · Moderate risk

Prasugrel HCI

Failed Dissolution Specifications. Notification from the manufacturer that lot is being recalled due to failed dissolution

Ongoing Dissolution failure Golden State Medical Supply Inc. D-0847-2026
Class II · Moderate risk

Carbamazepine Tablets

CGMP deviations: tablets with black specks.

Ongoing cGMP deviation Golden State Medical Supply Inc. NDC 51407-215-10 D-0771-2026
Class II · Moderate risk

GSMS Incorporated

Failed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hour timepoint.

Ongoing Dissolution failure Golden State Medical Supply Inc. NDC 51407-268-90 D-0587-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Golden State Medical Supply Inc. NDC 51407-638-01 D-0535-2026